Novavax Inc (NVAX) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of disease...
Novavax Inc (NVAX) currently trades at a P/E ratio of 4.10 (historical range: 2.02–5.67, median: 3.36), placing it at the 71th percentile — above its historical average, P/S ratio of 2.48 (range: 0.77–3.04, 93th percentile — expensive relative to its history).
Over the historical period (2024-08-30 to 2026-08-28), Novavax Inc's P/E ratio has expanded by 47% over the observed period (from an average of 2.7 to 4.0).
Novavax Inc appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 4.10 | 2.02 | 3.36 | 5.67 | 71th | above its historical average |
| P/S Ratio | 2.48 | 0.77 | 1.43 | 3.04 | 93th | expensive relative to its history |